Anti-Zika Virus (ZIKV) E Protein [Clone ZV67] - Purified in vivo GOLD™ Functional Grade

Clone ZV67 is primarily used in mouse studies for passive immunotherapy to evaluate protective efficacy against Zika virus (ZIKV) infection. This monoclonal antibody, which targets the lateral ridge of domain III (DIIILR) of the Zika virus envelope protein, has demonstrated significant therapeutic potential in several experimental contexts.

Lethal Challenge Protection Studies

The most common application involves passive transfer experiments where ZV67 is administered to mice before lethal ZIKV challenge. In these studies, 45 weekold C57BL/6 mice receive the antibody (typically 250 μg) along with antiIfnar antibody one day before infection with pathogenic ZIKV strains. This approach has consistently demonstrated that ZV67 provides complete clinical protection against lethal infection, reducing viremia and preventing the weight loss and mortality observed in control animals.

Heterologous Strain Protection

ZV67 has proven effective against multiple ZIKV strains in vivo, including the highly pathogenic African strain Dakar 41519. The antibody's broad neutralizing capacity makes it valuable for testing crossstrain protection, particularly important given ZIKV's genetic diversity across different geographic lineages.

Vaccine and Immunogen Development

ZV67 serves as a critical tool in vaccine research, being used as a positive selection target in phage display experiments to identify and validate resurfaced ZIKV envelope domain III immunogens. Researchers use ZV67 binding as a benchmark to ensure that modified antigens retain immunologically relevant epitopes while potentially reducing offtarget responses.

The antibody's consistent protective activity in stringent mouse models deficient in type I interferon signaling has established it as a standard reference for evaluating novel therapeutic antibodies and vaccine candidates against ZIKV infection.

Some of the most commonly used antibodies or proteins studied alongside ZV67 in the literature are other mouse monoclonal antibodies targeting Zika virus Domain III (DIII), particularly ZV2, ZV48, ZV54, and ZV64. These antibodies are frequently used in panels for structural, functional, competition, and neutralization studies.

Key details regarding commonly coused antibodies and proteins:

• ZV2, ZV48, ZV54, ZV64: These are ZIKV DIIIspecific mouse monoclonal antibodies used with ZV67 to map epitopes, determine competitive and noncompetitive binding, study neutralization, and define structural interfaces.
• CHK166: Sometimes used as a control antibody in functional assays involving ZIKV infection in vivo.
• AntiIfnar1 mAb: Used for passive transfer experiments in mice alongside ZV antibodies for protection studies.
• AntiFLAG antibody M2: Used as a control or reference in certain ELISAbased studies involving binding with ZV67 and related mAbs.
• 4G2: A positive control mAb that recognizes a different epitope (DI/II of E protein) and is used to provide context for DIIIspecificity in binding assays.
• ZIKV E DIII proteins or variants: Structural studies utilize recombinant Zika virus envelope DIII proteins or resurfaced DIII mutants to dissect the binding profiles and specific epitope recognition of ZV67 and its related antibodies.

Most literature involving ZV67 engages the above panel of mouse mAbs to elucidate precise epitope mapping, antibody competition, and functional importance, as their epitopes are close but nonoverlapping or, in some cases, competitive within ZIKV DIII. Control antibodies such as 4G2 and CHK166, as well as engineered DIII proteins, also frequently appear in studies with ZV67 for experimental validation or as assay standards.

Key findings from scientific literature on clone ZV67 consistently highlight its importance as a potent, broadly neutralizing, and structurally wellcharacterized monoclonal antibody targeting Zika virus (ZIKV):

• Broad and Potent Neutralizing Activity
  ZV67 exhibits strong neutralizing potency across a wide range of ZIKV strains, maintaining effectiveness against both African and American lineages. This distinguishes it from other monoclonal antibodies such as ZV48 and ZV64, whose activity is more strainrestricted.

• Epitope Specificity: Lateral Ridge on Domain III (DIII)
  ZV67 targets a highly specific and structurally conserved epitope on the lateral ridge (LR) of ZIKV's envelope protein domain III. This epitope is composed of four secondary structure elements: the Astrand, B–C loop, D–E loop, and F–G loop. ZV67 makes contact with 21 residues in this region.

• Structural and Evolutionary Insights
  The LR epitope recognized by ZV67 overlaps significantly with epitopes targeted by monoclonal antibodies against related flaviviruses, including E16 (West Nile virus) and DV1E106 (dengue virus), demonstrating evolutionary conservation of crucial neutralizing sites.

• Protective Efficacy in Animal Models
  ZV67 provides protection against lethal ZIKV challenge in mouse models, including effective neutralization of African ZIKV strains, highlighting its therapeutic potential.

• Escape Mutations
  Deep mutational scanning and neutralization assays showed that single amino acid mutations at key contact points can confer escape from ZV67 neutralization, completely abolishing its effect. This identifies potential viral escape routes and underscores the antibody's precise epitope dependence.

• Molecular Relationships with Other Antibodies
  Sequence analyses show high similarity between ZV67 and another potent antibody, ZV54, explaining their shared neutralization and protection profiles. This suggests both antibodies may derive from similar Bcell responses or represent optimally matured variants targeting the same key site.

• Utility in Vaccine Design and Epitope Mapping
  ZV67 has been used as a "selection tool" in vaccine development and structural studies to ensure engineered ZIKV immunogens preserve neutralizing epitopes, particularly the lateral ridge, while allowing modifications elsewhere.

In summary, ZV67 is a lead candidate for ZIKV therapy, a critical reagent for epitope mapping and vaccine design, and a model for understanding flavivirus neutralization. Studies involving ZV67 are foundational for both basic research and translational applications targeting Zika virus.

The dosing regimens of clone ZV67, a monoclonal antibody targeting the Zika virus, vary across different mouse models primarily due to factors such as mouse strain, immune competence, adjuvant selection, and dose schedule. These variations are tailored to maximize immunogenicity and protection in each model. For instance, different mouse strains (e.g., BALB/c, C57BL/6) may require different dosing strategies to achieve optimal immune responses. Additionally, the choice of adjuvant can affect the efficacy of the antibody in inducing protection against Zika virus infection.

In general, the dosing regimens are optimized to ensure that the antibody effectively neutralizes the virus and provides protection against lethal challenges. This involves adjusting the dose amount and frequency based on the specific requirements of each mouse model. However, specific details about the exact dosing schedules (e.g., amount per dose, frequency of administration) for ZV67 in various mouse models are not explicitly outlined in the available information.

Key Variables:

• Mouse Strain: Different strains may respond differently to the same dosing regimen.
• Immune Competence: The level of immune system functionality in the mice can influence the effectiveness of the dosing regimen.
• Adjuvant Selection: The type of adjuvant used can impact the immune response generated by the antibody.
• Dose Schedule: The timing and amount of each dose can be adjusted based on the model's requirements.

These factors are crucial in designing effective dosing regimens for ZV67 in mouse models to ensure optimal protection against Zika virus infection.